CD8A and ovarian cancer: As immunotherapy is emerging as a mainstay of anticancer strategies in several malignancy types including ovarian cancer, novel avenues for therapeutically targeting the pro-tumorigenic CAFs through modulation of CD8+ T cells are highly inspiring to both scientific and clinical communities.